Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol MYOV. Citi, Cowen & Company, Evercore ISI and Barclays acted as lead managers on the deal. Parent company Roivant Sciences also brought Axovant Sciences (AXON) public in 2015.
